Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, P. R. China.
Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, 100053, P. R. China.
J Integr Neurosci. 2020 Sep 30;19(3):561-570. doi: 10.31083/j.jin.2020.03.4.
Erythropoietin has been researched for its neuroprotective effects in ischemic stroke for over 30 years. Although erythropoietin can cause side effects that need to be controlled, it has been suggested to be effective in enhancing the prognosis of patients who are out of the therapeutic time window and have not received recombinant tissue plasminogen activator therapy. Studies on the mechanism of the function of erythropoietin have shown that it has various protective effects in ischemic brain injury after stroke, including promoting neurogenesis. In this review, we discuss the effects of erythropoietin on neurogenesis after ischemic brain injury and provide references for effective treatments for ischemic stroke, which is one of the leading causes of death worldwide.
促红细胞生成素在缺血性脑卒中的神经保护作用研究已经超过 30 年。尽管促红细胞生成素可能会引起需要控制的副作用，但它被认为对超过溶栓治疗时间窗且未接受重组组织型纤溶酶原激活剂治疗的患者的预后有改善作用。对促红细胞生成素功能机制的研究表明，其在脑卒中后缺血性脑损伤中有多种保护作用，包括促进神经发生。本文就促红细胞生成素对缺血性脑损伤后神经发生的影响进行综述，为缺血性脑卒中这一全球主要致死病因的有效治疗提供参考。
